Biogen CEO to Retire Following Alzheimer’s Drug Release,

biogenic said on Tuesday He said he would replace his CEO and effectively abandon the marketing of a high-profile Alzheimer’s drug that has failed commercially since its controversial approval nearly a year ago. Biogen said Michel Vounatsos, who has led the drugmaker for more than five years and presided over the approval and launch of …